Wedbush Analyst Reiterates Outperform Rating for CATX
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy CATX?
Source: NASDAQ.COM
- Clinical Trial Update: Perspective Therapeutics presented updated clinical data for its VMT-a-NET program at the AACR Annual Meeting, with 64 patients treated to date, demonstrating efficacy in neuroendocrine tumor treatment, and is on track to complete nearly one year of follow-up for 46 patients by mid-2026.
- Positive Market Outlook: Analyst David Nierengarten reiterated an Outperform rating for CATX with a 12-month price target of $11, reflecting confidence in the company's growth potential, especially with meaningful data and regulatory catalysts expected in the near future.
- Competitive Advantage: With SNY deprioritizing AlphaMedix, VMT-a-NET is positioned as a frontrunner in targeted alpha therapy, further solidifying its market position and potentially attracting more investor interest.
- Stock Performance Review: CATX has traded between $1.86 and $6.16 over the past year, closing at $4.55 on Monday with an 8.33% increase, indicating a positive market reaction to its clinical advancements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CATX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CATX
Wall Street analysts forecast CATX stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.760
Low
4.00
Averages
11.82
High
18.00
Current: 3.760
Low
4.00
Averages
11.82
High
18.00
About CATX
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perspective Therapeutics Announces Upcoming Corporate Updates for May 2026
- Strategic Event Schedule: Perspective Therapeutics will hold an analyst event on May 4, 2026, to discuss the company's strategy, enabling technology, and pipeline, which is expected to attract investor interest and enhance market confidence.
- Financial Results Release: The company will release its first-quarter financial results on May 11, 2026, in a press release format only, which may still influence investor perceptions of the company's financial health.
- Industry Conference Participation: Perspective will participate in the BofA Securities and RBC Capital Markets healthcare conferences on May 13 and 19, 2026, showcasing its latest advancements in radiopharmaceutical development and further enhancing its industry visibility.
- Innovative Technology Introduction: The company is developing targeted radiation therapy technology utilizing the isotope 212Pb, combined with imaging diagnostics, aimed at personalizing cancer treatment to improve efficacy and minimize toxicity, demonstrating its leading position in cancer treatment.
See More
Wedbush Analyst Reiterates Outperform Rating for CATX
- Clinical Trial Update: Perspective Therapeutics presented updated clinical data for its VMT-a-NET program at the AACR Annual Meeting, with 64 patients treated to date, demonstrating efficacy in neuroendocrine tumor treatment, and is on track to complete nearly one year of follow-up for 46 patients by mid-2026.
- Positive Market Outlook: Analyst David Nierengarten reiterated an Outperform rating for CATX with a 12-month price target of $11, reflecting confidence in the company's growth potential, especially with meaningful data and regulatory catalysts expected in the near future.
- Competitive Advantage: With SNY deprioritizing AlphaMedix, VMT-a-NET is positioned as a frontrunner in targeted alpha therapy, further solidifying its market position and potentially attracting more investor interest.
- Stock Performance Review: CATX has traded between $1.86 and $6.16 over the past year, closing at $4.55 on Monday with an 8.33% increase, indicating a positive market reaction to its clinical advancements.
See More
Perspective Therapeutics to Attend Investor Conferences
- Investor Conference Participation: Perspective Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, engaging in presentations and one-on-one meetings with investors, which is expected to enhance the company's visibility and credibility among investors.
- Clinical Trial Progress: The company is conducting Phase 1/2a imaging and therapy trials for neuroendocrine tumors, melanoma, and solid tumors, utilizing its proprietary 212Pb isotope technology aimed at improving treatment efficacy and minimizing toxicity, potentially attracting more investor interest in its R&D capabilities.
- Technological Innovation: Perspective's
See More
Perspective Therapeutics Upgraded to Buy Rating
- Rating Upgrade: Perspective Therapeutics (CATX) has received an upgrade to a 'Buy' rating, indicating analysts' optimistic outlook on its future performance, which may attract more investor interest.
- Price Target Set: The average price target is set at $12.93, reflecting confidence in the company's growth potential, and if achieved, the stock price could see significant upside.
- Market Reaction Anticipation: The upgrade in rating and price target is likely to stimulate a positive market reaction towards CATX, potentially driving the stock price higher and boosting investor confidence.
- Increased Investor Attention: With the improved rating, CATX may attract more institutional investors, further enhancing its market liquidity and shareholder value.
See More
Perspective Therapeutics Reports Disappointing FY Results
- Disappointing Earnings: Perspective Therapeutics reported a FY non-GAAP EPS of -$1.40, missing expectations by $0.20, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company’s revenue of $0.9 million represents a 37.9% year-over-year decrease, falling short of expectations by $0.17 million, reflecting weak market demand that could hinder future growth.
- Decreased Cash Reserves: As of December 31, 2025, cash, cash equivalents, and short-term investments totaled approximately $145 million, down from $227 million in 2024, indicating increased liquidity pressure that may affect future investments and operational capabilities.
- Equity Financing Plan: Perspective Therapeutics announced a $175 million equity offering, which may alleviate short-term funding pressures but could dilute existing shareholders' stakes, impacting shareholder value.
See More
Perspective Therapeutics to Announce Q4 Earnings on March 16
- Earnings Announcement: Perspective Therapeutics is set to release its Q4 earnings on March 16 after market close, with consensus estimates predicting an EPS of -$0.34 and revenue of $0.24 million, providing crucial insights into the company's financial health.
- Equity Offering: The company recently priced a $175 million equity offering, which will support its ongoing research in the SSTR2 solid tumor targeting space, potentially enhancing its market competitiveness and future growth prospects.
- Market Reaction: Following the equity offering announcement, shares of Perspective Therapeutics saw an uptick, indicating increased investor confidence in the company's future, which may set a positive tone for the upcoming earnings report.
- Industry Conference Participation: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, further elevating its visibility among investors and within the industry, showcasing its ongoing efforts and strategic positioning in the tumor targeting treatment sector.
See More
Perspective Therapeutics Announces Upcoming Corporate Updates for May 2026
- Strategic Event Schedule: Perspective Therapeutics will hold an analyst event on May 4, 2026, to discuss the company's strategy, enabling technology, and pipeline, which is expected to attract investor interest and enhance market confidence.
- Financial Results Release: The company will release its first-quarter financial results on May 11, 2026, in a press release format only, which may still influence investor perceptions of the company's financial health.
- Industry Conference Participation: Perspective will participate in the BofA Securities and RBC Capital Markets healthcare conferences on May 13 and 19, 2026, showcasing its latest advancements in radiopharmaceutical development and further enhancing its industry visibility.
- Innovative Technology Introduction: The company is developing targeted radiation therapy technology utilizing the isotope 212Pb, combined with imaging diagnostics, aimed at personalizing cancer treatment to improve efficacy and minimize toxicity, demonstrating its leading position in cancer treatment.
See More
Wedbush Analyst Reiterates Outperform Rating for CATX
- Clinical Trial Update: Perspective Therapeutics presented updated clinical data for its VMT-a-NET program at the AACR Annual Meeting, with 64 patients treated to date, demonstrating efficacy in neuroendocrine tumor treatment, and is on track to complete nearly one year of follow-up for 46 patients by mid-2026.
- Positive Market Outlook: Analyst David Nierengarten reiterated an Outperform rating for CATX with a 12-month price target of $11, reflecting confidence in the company's growth potential, especially with meaningful data and regulatory catalysts expected in the near future.
- Competitive Advantage: With SNY deprioritizing AlphaMedix, VMT-a-NET is positioned as a frontrunner in targeted alpha therapy, further solidifying its market position and potentially attracting more investor interest.
- Stock Performance Review: CATX has traded between $1.86 and $6.16 over the past year, closing at $4.55 on Monday with an 8.33% increase, indicating a positive market reaction to its clinical advancements.
See More
Perspective Therapeutics to Attend Investor Conferences
- Investor Conference Participation: Perspective Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, engaging in presentations and one-on-one meetings with investors, which is expected to enhance the company's visibility and credibility among investors.
- Clinical Trial Progress: The company is conducting Phase 1/2a imaging and therapy trials for neuroendocrine tumors, melanoma, and solid tumors, utilizing its proprietary 212Pb isotope technology aimed at improving treatment efficacy and minimizing toxicity, potentially attracting more investor interest in its R&D capabilities.
- Technological Innovation: Perspective's
See More
Perspective Therapeutics Upgraded to Buy Rating
- Rating Upgrade: Perspective Therapeutics (CATX) has received an upgrade to a 'Buy' rating, indicating analysts' optimistic outlook on its future performance, which may attract more investor interest.
- Price Target Set: The average price target is set at $12.93, reflecting confidence in the company's growth potential, and if achieved, the stock price could see significant upside.
- Market Reaction Anticipation: The upgrade in rating and price target is likely to stimulate a positive market reaction towards CATX, potentially driving the stock price higher and boosting investor confidence.
- Increased Investor Attention: With the improved rating, CATX may attract more institutional investors, further enhancing its market liquidity and shareholder value.
See More
Perspective Therapeutics Reports Disappointing FY Results
- Disappointing Earnings: Perspective Therapeutics reported a FY non-GAAP EPS of -$1.40, missing expectations by $0.20, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company’s revenue of $0.9 million represents a 37.9% year-over-year decrease, falling short of expectations by $0.17 million, reflecting weak market demand that could hinder future growth.
- Decreased Cash Reserves: As of December 31, 2025, cash, cash equivalents, and short-term investments totaled approximately $145 million, down from $227 million in 2024, indicating increased liquidity pressure that may affect future investments and operational capabilities.
- Equity Financing Plan: Perspective Therapeutics announced a $175 million equity offering, which may alleviate short-term funding pressures but could dilute existing shareholders' stakes, impacting shareholder value.
See More
Perspective Therapeutics to Announce Q4 Earnings on March 16
- Earnings Announcement: Perspective Therapeutics is set to release its Q4 earnings on March 16 after market close, with consensus estimates predicting an EPS of -$0.34 and revenue of $0.24 million, providing crucial insights into the company's financial health.
- Equity Offering: The company recently priced a $175 million equity offering, which will support its ongoing research in the SSTR2 solid tumor targeting space, potentially enhancing its market competitiveness and future growth prospects.
- Market Reaction: Following the equity offering announcement, shares of Perspective Therapeutics saw an uptick, indicating increased investor confidence in the company's future, which may set a positive tone for the upcoming earnings report.
- Industry Conference Participation: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, further elevating its visibility among investors and within the industry, showcasing its ongoing efforts and strategic positioning in the tumor targeting treatment sector.
See More
